2019-nCoV Clinical Trial
Official title:
An Exploratory Clinical Study on the Treatment of Acute Severe 2019-nCoV Pneumonia With Immunoglobulin From Cured 2019-nCoV Pneumonia Patients
The new coronavirus pneumonia is an acute infectious pneumonia. The pathogen is a previously unknown new coronavirus, namely 2019 new coronavirus (2019 novel coronavirus, 2019 nCoV). However, there is no specific anti-viral drug. It has been found that the specific antibodies against virus antigen are produced after these patients were cured, which could block the infection of 2019 nCoV on the host cells. At present, immunoadsorption is the most direct, rapid and effective method to separate immunoglobulin from the cured patients. Therefore, the study aims to prepare the immunoglobulin from 2019-ncov pneumonia cured patients, evaluate the efficacy and safety of the immunoglobulin in 2019-ncov pneumonia cured patients on the treatment of acute severe 2019-ncov pneumonia, and provide a new strategy for the treatment of 2019-ncov pneumonia.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Suspended |
NCT04334967 -
Hydroxychloroquine in Patients With Newly Diagnosed COVID-19 Compared to Standard of Care
|
Phase 4 | |
Withdrawn |
NCT04272710 -
Prognositc Factors in COVID-19 Patients Complicated With Hypertension
|
||
Completed |
NCT04260594 -
Clinical Study of Arbidol Hydrochloride Tablets in the Treatment of Pneumonia Caused by Novel Coronavirus
|
Phase 4 | |
Active, not recruiting |
NCT04273763 -
Evaluating the Efficacy and Safety of Bromhexine Hydrochloride Tablets Combined With Standard Treatment/ Standard Treatment in Patients With Suspected and Mild Novel Coronavirus Pneumonia (COVID-19)
|
N/A | |
Not yet recruiting |
NCT04270383 -
Clinical Characteristics and Long-term Prognosis of 2019-nCoV Infection in Children
|
||
Terminated |
NCT04261907 -
Evaluating and Comparing the Safety and Efficiency of ASC09/Ritonavir and Lopinavir/Ritonavir for Novel Coronavirus Infection
|
N/A | |
Not yet recruiting |
NCT04261426 -
The Efficacy of Intravenous Immunoglobulin Therapy for Severe 2019-nCoV Infected Pneumonia
|
Phase 2/Phase 3 | |
Recruiting |
NCT04255017 -
A Prospective/Retrospective,Randomized Controlled Clinical Study of Antiviral Therapy in the 2019-nCoV Pneumonia
|
Phase 4 | |
Recruiting |
NCT04254874 -
A Prospective/Retrospective,Randomized Controlled Clinical Study of Interferon Atomization in the 2019-nCoV Pneumonia
|
Phase 4 | |
Not yet recruiting |
NCT04356508 -
COVID-19: A Pilot Study of Adaptive Immunity and Anti-PD1
|
Phase 2 | |
Terminated |
NCT04321928 -
Personalized Health Education Against the Health Damage of Novel Coronavirus (COVID-19) Outbreak in Hungary
|
N/A |